online pharmacy, prescription drugs online



Drugs online research references









  • Rx drugs
  • The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients.
  • Effects of metformin on gonadotropin-induced ovulation in patients with polycystic ovary syndrome
  • 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes.
  • Decrease in serum C-reactive protein levels by troglitazone is associated with pretreatment insulin resistance, but independent of its effect on glycemia, in type 2 diabetic subjects.
  • Metformin relaxes rat tail artery by repolarization and resultant decreases in Ca2+ influx and intracellular Ca2+.
  • Exenatide: AC 2993, AC002993, AC2993A, Exendin 4, LY2148568.
  • Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome
  • Metformin protects against carbon tetrachloride hepatotoxicity in mice.
  • Rx drugs
  • The antidiabetic drug metformin decreases cholesterol metabolism in cultured human fibroblasts.
  • Rx drugs
  • Pharmacologic Therapy for HIV-Associated Lipodystrophy.
  • Combination of metformin and thiazolidindiones restore insulin signalling in insulin-resistant cultured myotubes.
  • Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion.
  • Dexamethasone reduces androgen levels in metformin-treated patients with polycystic ovary syndrome.
  • Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial.
  • The treatment of polycystic ovary syndrome.
  • Interaction between diazepam and oral antidiabetic agents on serum glucose, insulin and chromium levels in rats.
  • Effects of metformin therapy on plasma amino acid pattern in patients with maturity-onset diabetes.
  • Physiopathological approach to pathological hyperlactatemia in the diabetic patient. Value of blood metformin
  • Safety and efficacy of metformin in a restricted formulary.
  • Reduction of metformin renal tubular secretion by cimetidine in man.
  • Chronic lathyrism and atheromatosis in the rat. Protective effect of metformin.
  • Hypoglycemic effects of the blended Chinese traditional medicines in genetically and chemically diabetic mice
  • Effect of metformin on lipid metabolism in the rabbit aortic wall.
  • Treatment of diabetics with metformin
  • Energy expenditure in type 2 diabetic patients on metformin and sulphonylurea therapy.
  • Accumulation of metformin by tissues of the normal and diabetic mouse.
  • Can metformin reduce insulin resistance in polycystic ovary syndrome?
  • Effects of glibenclamide and metformin (alone or in combination) on insulin release from isolated human pancreatic islets.
  • Effects of central metformin administration on responses to air-jet stress and on arterial baroreflex function in spontaneously hypertensive rats.
  • Postreceptor effect of metformin on insulin action in mice.
  • Ovulation induction for polycystic ovary syndrome.
  • Carbohydrate biguanides as potential hypoglycemic agents.
  • Do metformin and phenformin potentiate differently B-cell response to high glucose? An in vitro study on isolated rat pancreas.
  • Metformin decreases blood pressure and obesity in OLETF rats via improvement of insulin resistance.
  • Metformin in management of pregnant insulin-independent diabetics.
  • Metformin-like effects of Quei Fu Di Huang Wan, a Chinese herbal mixture, on streptozotocin-induced diabetic rat.
  • Insulin secretion and repaglinide
  • The treatment of insulin resistance does not improve adrenal cytochrome P450c17alpha enzyme dysregulation in polycystic ovary syndrome.
  • Troglitazone prevents and reverses dexamethasone induced insulin resistance on glycogen synthesis in 3T3 adipocytes.
  • Sulphonylureas and biguanides do not affect insulin binding in H35 hepatoma cells.
  • Potentiating effect of metformin on insulin-induced glucose uptake and glycogen metabolism with Xenopus oocytes.
  • Proinsulin and insulin secretion in obese females before and after administration of metformin
  • Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells.
  • Metformin enhances insulin signalling in insulin-dependent and-independent pathways in insulin resistant muscle cells.
  • Effect of Luffa aegyptiaca (seeds) and Carissa edulis (leaves) extracts on blood glucose level of normal and streptozotocin diabetic rats.
  • Cross-linked high amylose starch derivatives as matrices for controlled release of high drug loadings.
  • The influence of streptozotocin diabetes and metformin on erythrocyte volume and on the membrane potential and the contractile characteristics of the extensor digitorum longus and soleus muscles in rats.
  • Effect of acute and sub-chronic administration of the imidazoline compound S 22068 on in vivo glucose and insulin responses in normal lean CBA/Ca mice.
  • Characterization of sulfonylurea receptors in isolated human pancreatic islets.
  • Effects of some non-ionic surfactants on transepithelial permeability in Caco-2 cells.
  • Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
  • Hypolipidemic effects of metformin in hyperprebetalipoproteinemia.
  • Metformin as secondary therapy in a defined population with type 2 diabetes.
  • Insulin sensitizer. A new therapy option for type 2 diabetic patients
  • Clinical, biophysical and biochemical variables from African-heritage subjects with type 2 diabetes.
  • Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.
  • Effect of chronic metformin treatment of hepatic and muscle glycogen metabolism in KK mice.
  • Metformin increases glucose transporter protein and gene expression in human fibroblasts.
  • A retrospective analysis of the efficacy and safety of metformin in the African-American patient.
  • Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats.
  • Effect of metformin treatment on insulin action in diabetic rats: in vivo and in vitro correlations.
  • Effect of metformin treatment on glucose tolerance and glomerulosclerosis in KK mice.
  • Effects of the biguanide metformin on splanchnic blood flow in rats: preferential and dose-dependent increase in islet blood flow.
  • Median-term (4 months) treatment with glibenclamide + metformin substituting for glibenclamide + fenformin lowers the lacticemia levels in type-2 diabetics (NIDDM)
  • Metformin in the digestive tract.
  • Human placental glucose uptake and transport are not altered by the oral antihyperglycemic agent metformin.
  • High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome.
  • A comparison of metformin versus guar in combination with sulphonylureas in the treatment of non insulin dependent diabetes.
  • Clinical risk associated with contrast angiography in metformin treated patients: a clinical review.
  • Effectiveness of treatment with metformin in patients with type 2 diabetes mellitus poorly controlled with insulin treatment
  • Prevention of pancreatic cancer induction in hamsters by metformin.
  • Inhibition of carbohydrate-induced hypertriglyceridemia by metformin.
  • Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin.
  • Diurnal pattern of plasma metformin concentrations and its relation to metabolic effects in type 2 (non-insulin-dependent) diabetic patients.
  • Combination daytime chlorpropamide-metformin/bedtime insulin in the treatment of secondary failures in non insulin dependent diabetes.
  • Cardiovascular actions of chronic intracerebroventricular administration of metformin in normotensive rats.
  • Effects of the biguanide class of oral hypoglycemic agents on mouse embryogenesis.
  • Metabolic effects of combined sulphonylurea and metformin therapy in maturity-onset diabetice.
  • The effects of metformin compared to the effects of phenformin on the lactate production and the metabolism of isolated parenchymal rat liver cell.
  • Use of cellulose ether containing excipients with microcrystalline cellulose for the production of pellets containing metformin hydrochloride by the process of extrusion-spheronization.
  • Effect of plasma metformin concentrations on serum lipid levels in type II diabetic patients.
  • A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose.
  • Dual effect of metformin in cultured rat hepatocytes: potentiation of insulin action and prevention of insulin-induced resistance.
  • Elevated GLUT 1 level in crude muscle membranes from diabetic Zucker rats despite a normal GLUT 1 level in perineurial sheaths.
  • Light and electron microscopic study of hepatic lesions in the course of hyperlactatemia in diabetic patients
  • Metformin-induced lactic acidosis: potentiation by ethanol.
  • Metformin ameliorates diabetes but does not normalize the decreased GLUT 4 content in skeletal muscle of obese (fa/fa) Zucker rats.
  • Management of type 2 diabetes mellitus with special reference to metformin therapy.
  • Pathogenesis of type 2 diabetes mellitus.
  • Metformin does not alter diabetes incidence in the NOD mouse.
  • A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat.
  • Hyperinsulinemia and disorders of the menstrual cycle
  • Metformin blocks downregulation of cell surface GLUT4 caused by chronic insulin treatment of rat adipocytes.
  • Diarrhea and metformin in a diabetic clinic.
  • Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.
  • Bioequivalence of a generic metformin tablet preparation.
  • Mechanism of metformin action in non-insulin-dependent diabetes.
  • Differential inhibitory effects of antidiabetic drugs on arterial smooth muscle cell proliferation.
  • Association of Metformin's effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from intracellular pool to plasma membrane in rat adipocytes.
  • Type 2 diabetes in the elderly: an assessment of metformin (metformin in the elderly).
  • Metformin does not increase energy expenditure of brown fat.
  • Action of metformin on erythrocyte membrane fluidity in vitro and in vivo.
  • Effects of an ethanolic extract of Gynura procumbens on serum glucose, cholesterol and triglyceride levels in normal and streptozotocin-induced diabetic rats.
  • Acute sympathoinhibitory actions of metformin in spontaneously hypertensive rats.
  • Metformin improves cardiac functional recovery after ischemia in rats.
  • Effects of metformin and glibenclamide on insulin receptors in fibroblasts and tumor cells in vitro.
  • Subcellular distribution of metformin in rat liver.
  • Sulfonylurea receptor gene 16-3 polymorphism - association with sulfonylurea or insulin treatment in type 2 diabetic subjects.
  • Demonstration of defective glucose uptake and storage in erythrocytes from non-insulin dependent diabetic patients and effects of metformin.
  • Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin.
  • Effects of metformin on glucose metabolism of isolated perfused rat skeletal muscle.
  • Effect of metformin on glucose metabolism in mouse soleus muscle.
  • Effects of improved glycaemic control on calcium and magnesium homeostasis in type II diabetes.
  • Preliminary findings on 2 groups of diabetics with regard to platelet aggregation in relation to retinopathy and ultimate relation to antidiabetic therapy
  • Effect of metformin on hepatocyte insulin receptor binding in normal, streptozotocin diabetic and genetically obese diabetic (ob/ob) mice.
  • Effects of metformin on hyperinsulinemic anovulation
  • The effect of metformin on adipose tissue metabolism and peripheral blood flow in subjects with NIDDM.
  • Metformin reduces platelet hypersensitivity in hypercholesterolemic rabbits.
  • Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells.
  • The effect of oral hypoglycaemic agents on dyslipidaemia in Nigerian patients with newly diagnosed non-insulin dependent diabetes mellitus--a prospective study.
  • Demonstration of the hypoglycemic action of Momordica charantia in a validated animal model of diabetes.
  • Utility of metformin as an adjunct to hydroxycitrate/carnitine for reducing body fat in diabetics.
  • Evidence that metformin increases insulin-stimulated glucose transport by potentiating insulin-induced translocation of glucose transporters from an intracellular pool to the cell surface in rat adipocytes.
  • Anti-diabetic biguanides inhibit hormone-induced intracellular Ca2+ concentration oscillations in rat hepatocytes.
  • Chronic insulin effects on insulin signalling and GLUT4 endocytosis are reversed by metformin.
  • Co-secretion of amylin and insulin from cultured islet beta-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents.
  • Metformin decreases plasma insulin levels and systolic blood pressure in spontaneously hypertensive rats.
  • Determination of metformin in plasma by capillary electrophoresis using field-amplified sample stacking technique.
  • Metformin increases insulin-stimulated glucose transport in insulin-resistant human skeletal muscle.
  • Maturation of regenerating nerve assessed by evoked potential in the rat: hyperbolic time course.
  • Effect of metformin on insulin-stimulated glucose turnover and insulin binding to receptors in type II diabetes.
  • Effect of metformin on insulin binding to receptors in cultured human lymphocytes and cancer cells.
  • Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients.
  • Effects of metformin on insulin receptor tyrosine kinase activity in rat adipocytes.
  • Effects of metformin on intestinal 5-hydroxytryptamine (5-HT) release and on 5-HT3 receptors.
  • Changes in hepatic and intestinal cholesterol regulatory enzymes. The influence of metformin.
  • Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects.
  • Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study.
  • Glycosylated hemoglobin and its temporal relationship to plasma glucose in non-insulin dependent (type 2) diabetes mellitus.
  • A study of the United Kingdom Prospective Diabetes Study and its results
  • Repaglinide and diabetes: new preparation. No better than glucose-lowering sulphonamides.
  • Metformin-induced lacticacidemia in patients with type 2 diabetes mellitus.
  • Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.
  • The effect of metformin on liver blood flow in vivo in normal subjects and patients with non insulin dependent diabetes.
  • Plasma high density lipoprotein cholesterol in streptozotocin diabetic and non-diabetic mice after prolonged administration of glibenclamide, chlorpropamide and metformin.
  • Effects of Averrhoa bilimbi leaf extract on blood glucose and lipids in streptozotocin-diabetic rats.
  • The effect of metformin on lactate levels in type II diabetes
  • Metformin and contrast media: where is the conflict?
  • Evidence that metformin ameliorates cellular insulin-resistance by potentiating insulin-induced translocation of glucose transporters to the plasma membrane.
  • Oxidative stress and metabolic control in non-insulin dependent diabetes mellitus.
  • Changes in carbohydrate metabolism and efficiency of hypoglycemic drugs related to the light dark cycle in rats. A study on stimulated diaphragm
  • Effect of metformin on nitric oxide synthase in genetically obese (ob/ob) mice.
  • Postural stability in non-insulin dependent diabetics.
  • Nongenetic mouse models of non-insulin-dependent diabetes mellitus.
  • Hepatothermic therapy of obesity: rationale and an inventory of resources.
  • Anti-activator inhibitors of plasminogen
  • The KID Study. III: Impact of inpatient rehabilitation on the metabolic control of type I and type II diabetics--a one-year follow-up.
  • Intermittent administration of brain-derived neurotrophic factor ameliorates glucose metabolism in obese diabetic mice.
  • Hypoglycaemic effect of metformin in genetically obese (fa/fa) rats results from an increased utilization of blood glucose by intestine.
  • Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats.
  • Metaformin: an antiatherosclerotic agent modifying very low density lipoproteins in rabbits.
  • Differential therapy with oral antidiabetic drugs
  • In vitro antidiabetics-antacid interactions.
  • Changes in prescribing patterns of oral hypoglycaemics in elderly patients, over a period of 10 years: matching with general practitioners' perceptions of their own prescribing.
  • Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus.
  • Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation.
  • DBM mice as a pharmacological model of maturity onset diabetes. Studies with metformin.
  • Comparative effects of phenformin, metformin and glibenclamide on metabolic rhythms in maturity-onset diabetics.
  • Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus.
  • The acute effect of metformin on glucose production in the conscious dog is primarily attributable to inhibition of glycogenolysis.
  • Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity.
  • Review of management of type 2 diabetes mellitus.
  • Plasma t-PA and PAl-1 antigen concentrations in non-insulin dependent diabetic patients: effects of treatment modality on fibrinolysis.
  • Glycaemic and blood pressure controls achieved in a cohort of 318 patients with type 2 diabetes.
  • Oral hypoglycaemic agents in 118 diabetic pregnancies.
  • Rosiglitazone: a new therapy for Type 2 diabetes.
  • Use of antidiabetic and antihypertensive drugs in hospital and outpatient settings in Hong Kong.
  • How long can insulin therapy be avoided in the patient with type 2 diabetes mellitus by use of a combination of metformin and a sulfonylurea?
  • Effect of metformin on fatty acid and glucose metabolism in freshly isolated hepatocytes and on specific gene expression in cultured hepatocytes.
  • Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome.
  • Anorectic effect of metformin in lean and genetically obese hyperglycaemic (ob/ob) mice.
  • Info-Meeting. Pharmacologic prevention of the progression from impaired glucose tolerance to type 2 diabetes: favorable effects of metformin and acarbose
  • Rx drugs
  • Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome.
  • Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases
  • Reversal of diabetes-induced rat graft transplant coronary artery disease by metformin.
  • Circulating ghrelin levels in patients with polycystic ovary syndrome.
  • Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications.
  • Antihyperglycaemic and anti-oxidant properties of Andrographis paniculata in normal and diabetic rats.
  • Rx drugs
  • Enhanced secretion of glucagon-like peptide 1 by biguanide compounds.
  • Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat.
  • Metformin potentiates the antigluconeogenic action of insulin.
  • Chronic diseases management in the Jamaican setting: HOPE worldwide Jamaica's experience.
  • Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus.
  • Influence of new evidence on prescription patterns.
  • Rosiglitazone and pioglitazone: new preparations. Two new oral antidiabetics both poorly assessed.
  • Enteric-coated insulin capsules: a combination with or a replacement of oral hypoglycaemic drugs.
  • Vanadyl-biguanide complexes as potential synergistic insulin mimics.
  • Is programming of glucocorticoid receptor expression by prenatal dexamethasone in the rat secondary to metabolic derangement in adulthood?
  • Treatment of type 2 diabetes: inadequate assessment of oral antidiabetic combinations.
  • Rx drugs
  • Lactic acidosis and metformin implicated: why better information about risk factors?
  • Differential effects of metformin on bile salt absorption from the jejunum and ileum.
  • Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin.
  • Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes
  • Metabolic and cardiovascular effects of very-low-calorie diet therapy in obese patients with Type 2 diabetes in secondary failure: outcomes after 1 year.
  • Rx drugs
  • Optimizing the management of type 2 diabetics: results of the "DREAM" study in general practice
  • Bioadhesive delivery of metformin using prosopis gum with antidiabetic potential.
  • AMPK beta subunit targets metabolic stress sensing to glycogen.
  • Metformin treatment of lean and obese Zucker rats modulates the ability of glucagon and insulin to regulate hepatocyte adenylate cyclase activity.
  • The effect of metformin treatment to ovarian response in cases with PCOS.
  • Effect of long-term metformin treatment on the development of diabetes in genetically diabetic mice (DBM)
  • Should we screen diabetic patients using biguanides for megaloblastic anaemia?
  • Non-enzymatic fibrinolytic agents
  • Long-term efficacy of steady-dose metformin in type 2 diabetes mellitus: a retrospective study.
  • Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis.
  • Anthropometry and body composition in northern Asian Indian patients with type 2 diabetes: receiver operating characteristics (ROC) curve analysis of body mass index with percentage body fat as standard.
  • Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus.
  • Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome.
  • Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart.
  • Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects.
  • The syndrome of food-cobalamin malabsorption revisited in a department of internal medicine. A monocentric cohort study of 80 patients.
  • Contraindications to metformin therapy in patients with NIDDM.
  • Presentation and 5-year follow-up of type 2 diabetes mellitus in African-American and Caribbean-Hispanic adolescents.
  • Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death.
  • Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes.
  • Estimating the contribution of genes and environment to variation in renal drug clearance.
  • Metformin: drug of choice for the prevention of type 2 diabetes and cardiovascular complications in high-risk subjects.
  • Metformin-induced cholestatic hepatitis.
  • Genetic cause of hyperglycaemia and response to treatment in diabetes.
  • Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.
  • Rx drugs
  • The role of metformin in the management of polycystic ovary syndrome.
  • Effects of short term metformin administration on androgens in normal men.







    online pharmacies || Hair Million herbal formula for hair loss and hair growth || Amoxicillin || Tramadol || Paxil || Rx Drugs USA, Prescription Drugs Online Pharmacy || Zithromax || online pharmacy || Antibiotics and prescription medications online literature || Antibiotics